Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2017

Zhang R, Fruhwirth GO, Coban O, Barrett JE, Burgoyne T, Lee SH, et al. Probing the Heterogeneity of Protein Kinase Activation in Cells by Super-resolution Microscopy. ACS Nano. 2017;11(1):249-257.

Cayrol F, Praditsuktavorn P, Fernando TM, Kwiatkowski N, Marullo R, M Calvo-Vidal N, et al. THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. Nat Commun. 2017;8:14290.

Shukla S, Cyrta J, Murphy DA, Walczak EG, Ran L, Agrawal P, et al. Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance. Cancer Cell. 2017;32(6):792-806.e7.

Cayrol F, Praditsuktavorn P, Fernando TM, Kwiatkowski N, Marullo R, M Calvo-Vidal N, et al. Corrigendum: THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. Nat Commun. 2017;8:14747.

DeSimone RA, Wontakal SN, Lyashchenko AK, Schwartz J. Acute mechanical hemolysis as a complication of extracorporeal photopheresis in a low-weight child. J Clin Apher. 2017;32(6):571-573.

J Mulvey J, Matnani R, Cushing MM. Historical ABO blood group discrepancy: a blessing in disguise to unravel a medical identity theft. Transfusion. 2017;57(4):1096-1097.

Magro CM, Olson LC, Fulmer CG. CD30+ T cell enriched primary cutaneous CD4+ small/medium sized pleomorphic T cell lymphoma: A distinct variant of indolent CD4+ T cell lymphoproliferative disease. Ann Diagn Pathol. 2017;30:52-58.

Tsang HC, Mathew S, Magro CM. An Aggressive Primary Cutaneous Follicle Center Lymphoma With c-MYC Translocation and CDKN2A (9p21) Deletion: A Case Report and Review of the Literature. Am J Dermatopathol. 2017;39(3):e44-e49.

Natkunam Y, Gratzinger D, de Jong D, Chadburn A, Goodlad JR, Chan JK, et al. Immunodeficiency and Dysregulation: Report of the 2015 Workshop of the Society for Hematopathology/European Association for Haematopathology. Am J Clin Pathol. 2017;147(2):124-128.

Cheng E, Ko D, Nguyen M, Moo T-, Andreopoulou E, Hoda SA, et al. Residual Pure Intralymphatic Breast Carcinoma Following Neoadjuvant Chemotherapy Is Indicative of Poor Clinical Outcome, Even in Node-Negative Patients. Am J Surg Pathol. 2017;41(9):1275-1282.